Skip to main content

Table 1 Restitution of Classical (CP), Lectin (LP) and Alternative pathway (AP) activation in serum from 6 C2-deficient patients by addition of rhC2

From: Recombinant human complement component C2 produced in a human cell line restores the classical complement pathway activity in-vitro: an alternative treatment for C2 deficiency diseases

Restituted seruma

Patient no.

CP

LPc

AP

1

+++b

±

+++

2

+++

-

+++

3

+++

±

+++

4

+++

+

+++

5

+++

++

+++

6

+++

-

+++

  1. arhC2 was added to C2-deficient serum, final concentration 25 μg/ml.
  2. bComplement activation tested by ELISA. +++ = 100% activation, ++ = 50%, + = 20%, - = no activation.
  3. cLP activity reflects the MBL concentration governed by MBL genotype. Patient 5 is homozygous for the wild-type structural gene variant (genotype A/A), while the other patients are heterozygous for this allele.